Total revenues of the Merck Serono division grew in line with the forecasted average for the pharmaceutical industry. This growth was mainly driven by our two top-selling medicines, the biopharmaceuticals Rebif® and Erbitux®.
The Consumer Health Care division continued on a growth course in 2009. We consolidated our market position, underpinned by the success of our strategic brands and numerous new product launches.
Audited
back
